Landos Biopharma Announces Final Safety Results from Phase 1 Study of BT-11 in Healthy Volunteers; - BT-11 was safe and well-tolerated at all doses evaluated and supports initiation of Phase 2 program in IBD patients in 1st half of 2019 -

Press/Media

Period7 Jan 2019

Media coverage

3

Media coverage